CN114796293A - 一种常春藤皂苷c的应用 - Google Patents
一种常春藤皂苷c的应用 Download PDFInfo
- Publication number
- CN114796293A CN114796293A CN202210416547.4A CN202210416547A CN114796293A CN 114796293 A CN114796293 A CN 114796293A CN 202210416547 A CN202210416547 A CN 202210416547A CN 114796293 A CN114796293 A CN 114796293A
- Authority
- CN
- China
- Prior art keywords
- hederagenin
- skin
- group
- use according
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 title claims abstract description 30
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 title claims abstract description 30
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 title claims abstract description 30
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 title claims abstract description 30
- 208000017520 skin disease Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- -1 patch Substances 0.000 claims description 2
- 229940000033 dermatological agent Drugs 0.000 claims 4
- 239000003241 dermatological agent Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- RYHDIBJJJRNDSX-MCGLQMIESA-N Hederacoside C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC(=O)[C@@]34[C@@H](CC(C)(C)CC3)C=3[C@@]([C@]5(C)CC[C@H]6[C@](C)(CO)[C@@H](O[C@H]7[C@@H]([C@@H](O)[C@@H](O)CO7)O[C@H]7[C@@H]([C@H](O)[C@@H](O)[C@H](C)O7)O)CC[C@]6(C)[C@H]5CC=3)(C)CC4)O2)O)[C@H](O)[C@H]1O RYHDIBJJJRNDSX-MCGLQMIESA-N 0.000 claims 1
- MLWBUURUTWPMOO-UHFFFAOYSA-N Hederasaponin C Natural products CC1OC(OC2C(O)COC(OC3CCC4(C)C(CCC5(C)C4CC=C6C7CC(C)(C)CCC7(CCC56C)C(=O)OC8OC(COC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9O)C(O)C(O)C8O)C3(C)CO)C2O)C(O)C(O)C1O MLWBUURUTWPMOO-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 229940121657 clinical drug Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- RYHDIBJJJRNDSX-UHFFFAOYSA-N kalopanax-saponin B Natural products OC1C(O)C(O)C(C)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(OC(=O)C34C(CC(C)(C)CC3)C=3C(C5(C)CCC6C(C)(CO)C(OC7C(C(O)C(O)CO7)OC7C(C(O)C(O)C(C)O7)O)CCC6(C)C5CC=3)(C)CC4)O2)O)C(O)C1O RYHDIBJJJRNDSX-UHFFFAOYSA-N 0.000 claims 1
- 229940126701 oral medication Drugs 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000003860 topical agent Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 12
- 229960002751 imiquimod Drugs 0.000 description 10
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000037380 skin damage Effects 0.000 description 9
- 241000208341 Hedera Species 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 229960002475 halometasone Drugs 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005775 Parakeratosis Diseases 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LVTJOONKWUXEFR-UEZXSUPNSA-N protodioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O LVTJOONKWUXEFR-UEZXSUPNSA-N 0.000 description 2
- QDQWGYLCDZBAMD-UHFFFAOYSA-N saponin C Natural products CC1C2C3CCC4C5(C)CCC(O)C(C)(COC6OC(CO)C(O)C(O)C6O)C5CCC4(C)C3(C)CCC27C8OC8C1(C)OC7=O QDQWGYLCDZBAMD-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000073 effect on psoriasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- CSJDCSCTVDEHRN-UHFFFAOYSA-N methane;molecular oxygen Chemical compound C.O=O CSJDCSCTVDEHRN-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000013309 psoriasis mouse model Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种常春藤皂苷C的应用，具体为常春藤皂苷C在治疗皮肤病中的应用，本发明首次公开了常春藤皂苷C对咪喹莫特诱导的小鼠具有保护作用，能提高咪喹莫特诱导后小鼠的体重，降低PASI评分，改善皮肤红斑，减轻鳞屑浸润程度，改善皮损病理变化，发挥抗炎和免疫调节功能，可能成为潜在的皮肤病治疗药物。
Description
技术领域
本发明属于中药治疗技术，具体涉及常春藤皂苷C在制备治疗皮肤病药物中的应用。
背景技术
皂苷由皂苷元与糖构成，从分子结构来看，皂苷是由皂苷配基与糖、糖醛酸或者其它有机酸通过碳氧共价键相连接而成的，其中糖较为常见的有鼠李糖、葡萄糖、半乳糖、阿拉伯糖、木糖等。根据皂苷元结构的不同，皂昔可分为三萜皂苷、甾体皂苷两大类。在植物界中分布最广的是齐墩果烷型皂苷，主要存在于五加科和豆科植物中，在一些常见的中草药如人参、甘草、常春藤中都有（参见：中华常春藤中皂苷类成分和挥发油分离分析研究），常春藤皂苷C在常春藤中含量最高，收录洋常春藤作为植物药也是以洋常春藤叶片中常春藤皂苷C含量高于3%为主要含量指标（参见：近年来皂苷药理活性的研究概况），皂苷多为白色或乳白色粉末，少数为晶体，具有强吸湿性，其味苦而辛辣，对黏膜有刺激作用，可溶于水。银屑病发病机制是由于免疫系统、自身抗原以及多种环境因素之间相互作用而引发，与感染、外伤、环境及药物等诱发因素相关。近年来，中药成为银屑病治疗药物的研究的热点，但是未见涉及常春藤皂苷C的报道。
发明内容
近年对一些中药及从中药分离到的活性成分进行研究发现，具有清热凉血、活血化瘀、养血润燥为主,兼以健脾利湿、解毒散结的中药方剂及单味中药均有不同程度的抗银屑病作用，但是现有中药以汤剂为主，服用会带来肠胃不适等副作用。本发明以常春藤皂苷C为药物，发现对咪喹莫特诱导的小鼠具有保护作用，能提高咪喹莫特诱导后小鼠的体重，降低PASI评分，改善皮肤红斑， 减轻鳞屑浸润程度，改善皮损病理变化，发挥抗炎和免疫调节功能，可能成为潜在的银屑病治疗药物。
本发明公开了常春藤皂苷C在制备治疗皮肤病药物中的应用，具体的，常春藤皂苷C在制备治疗银屑病药物中的应用；常春藤皂苷C在制备治疗皮肤红斑药物中的应用；常春藤皂苷C在制备治疗鳞屑药物中的应用；常春藤皂苷C在制备治疗皮损肥厚药物中的应用；常春藤皂苷C在制备改善体重减轻的药物中的应用。优选的，所述皮肤红斑由银屑病导致；所述鳞屑由银屑病导致；所述皮损肥厚由银屑病导致；体重减轻由银屑病导致。
一种治疗皮肤病，尤其是银屑病药物，其活性成分为常春藤皂苷C，还包括常规药物辅料。
本发明中，药物为外用药物，剂型包括溶液剂、膏剂、贴剂、凝胶剂、喷膜剂、乳液剂等，可以用现有常规药用辅料进行配制。
本发明首次公开了常春藤皂苷C对咪喹莫特诱导的小鼠具有保护作用，能提高咪喹莫特诱导后小鼠的体重，降低PASI评分，改善皮肤红斑，减轻鳞屑浸润程度，改善皮损病理变化，发挥抗炎和免疫调节功能，可能成为潜在的银屑病治疗药物。
附图说明
图1为小鼠的皮肤HE染色图。
图2为小鼠PASI评分、红斑评分、鳞屑评分、增厚评分。
图3为小鼠背部皮肤照片。
图4为小鼠体重变化。
具体实施方式
常春藤皂苷C为现有物质，动物实验以及治疗效果分析为现有方法，符合苏州大学动物实验要求。实施例以常春藤皂苷C水溶液为例说明其作为外用药物对银屑病的疗效，其他外用剂型也具有近似疗效。
实施例一
常春藤皂苷C加入水中，配制常春藤皂苷C水溶液。
将25只Balb/c小鼠按体重随机分为正常对照组、模型组、卤米松阳性药组（5mg/kg）、常春藤皂苷C低剂量组（1mg/kg）、常春藤皂苷C高剂量组（3.3 mg/kg），每组5只。造模前３天，使用脱毛膏和剃毛机背部脱毛2cm×3cm范围，造模当天，观察小鼠背部脱毛情况，进行二次脱毛。除正常对照组外的小鼠，背部皮肤上涂抹约62.5mg IMQ乳膏（５%），正常对照组小鼠背部涂抹等量凡士林。卤米松组咪喹莫特造模后4小时涂抹卤米松乳膏。常春藤皂苷C给药组咪喹莫特造模后4小时涂抹常春藤皂苷C水溶液。模型组咪喹莫特造模后4小时涂抹0.1ml纯水。连续处理7 d。每日同一时间段用数码照相记录皮损变化，观察小鼠背部是否出现红斑、皮损肥厚、及鳞屑等银屑病的特征性改变，并记录PASI评分。小鼠银屑病样皮炎严重程度PASI评分方法:采用肉眼观察的方法评估小鼠背部去毛区皮损严重程度，参照国际通用的银屑病皮损面积及严重程度的评价方法(PASI)进行评估。按皮肤红斑、鳞屑、肥厚的特征，每个特征按严重程度采用0～4分评价:0=无;1=轻度;2=中度;3=重度;4=极重度，评分标准为现有常识。
图1为给药7天的小鼠皮肤HE染色图；图2为给药7天的小鼠PASI评分、红斑评分、鳞屑评分、增厚评分；图3为给药七天小鼠的背部皮肤照片；图4为给药7天的小鼠体重（g）变化。实验结果表明涂抹咪喹莫特后，与空白组相比，模型组皮肤出现红斑、鳞屑和浸润，产生类似银屑病样皮损。随着药物的持续作用，模型组从第 2～3 天开始皮损日益严重，鳞屑增多增厚，皮肤浸润明显，对照组与模型组PASI综合评分结果3～7天（P<0.01）均有统计学意义，表明银屑病小鼠模型建立成功。HE 染色后显微镜下观察比较小鼠背部皮肤组织的病变程度。与正常组相比，光学显微镜下观察到模型组小鼠皮损表皮显著增厚，并出现明显角化过度、角化不全，海绵水肿，血管扩张，充血明显等银屑病的特征性病理改变。常春藤皂苷C高剂量组能减小表皮增厚程度，减少角化过度、角化不全及棘层肥厚等，表明常春藤皂苷C对银屑病有良好的治疗作用。药物组皮肤与模型组相比同期的皮损症状有所减轻，皮肤增厚不明显，几乎无鳞屑。阳性药组皮肤微微泛红，鳞屑较少，浸润增厚较轻；高剂量组、低剂量组与模型组PASI综合评分差异结果在第7天（P<0.01）有统计学意义；卤米松阳性药组在4～7天（P<0.01）均有统计学意义。实验结果提示常春藤皂苷C对咪喹莫特引起的银屑病皮损改变具有保护作用。
给药5 天内，对照组、模型组、各个给药组体重（g）均下降，此后体重逐日增高直至第 7 天疗效观察期。与对照组相比，模型组、阳性药组体重下降尤为明显，其中模型组与对照组体重差异在第2～8 天均有统计学意义；高剂量组与模型组体重差异在第2～5、第8天（P<0.01）有统计学意义；阳性药组与模型组体重差异在第5天（P<0.05）、6～8天（P<0.01）均有统计学意义，低剂量组与模型组体重差异无统计学意义；高剂量组与卤米松阳性药组体重差异在第2～8天（P<0.01）均有统计学意义。实验结果提示常春藤皂苷C能明显改善咪喹莫特诱导的银屑病小鼠的体重减轻，糖皮质激素则呈现出明显的副作用，在用药七天内体重下降尤为明显，甚至超过模型组。
Claims (10)
1.一种治疗皮肤病药物，其活性成分为常春藤皂苷C。
2.根据权利要求1所述治疗皮肤病药物，其特征在于，所述治疗皮肤病药物包括常规药物辅料。
3.根据权利要求1所述治疗皮肤病药物，其特征在于，所述治疗皮肤病药物为外用药物。
4.常春藤皂苷C在制备治疗皮肤病药物中的应用。
5.根据权利要求4所述的应用，其特征在于，所述治疗皮肤病药物为外用药物。
6.根据权利要求4所述的应用，其特征在于，述治疗皮肤病药物的剂型为溶液剂、膏剂、贴剂、凝胶剂、喷膜剂或者乳液剂。
7.根据权利要求6所述的应用，其特征在于，所述溶液剂为纯水剂或者含有药物辅料的水剂。
8.根据权利要求4所述的应用，其特征在于，所述皮肤病由免疫或者炎症引起。
9.根据权利要求4所述的应用，其特征在于，所述常春藤皂苷C的给药剂量低于临床药物给药剂量。
10.根据权利要求9所述的应用，其特征在于，所述临床药物包括内服药、外用药、天然植物用药或者生物制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210416547.4A CN114796293B (zh) | 2022-04-20 | 2022-04-20 | 一种常春藤皂苷c的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210416547.4A CN114796293B (zh) | 2022-04-20 | 2022-04-20 | 一种常春藤皂苷c的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114796293A true CN114796293A (zh) | 2022-07-29 |
| CN114796293B CN114796293B (zh) | 2024-06-11 |
Family
ID=82505662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210416547.4A Active CN114796293B (zh) | 2022-04-20 | 2022-04-20 | 一种常春藤皂苷c的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796293B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200981A (zh) * | 2019-06-06 | 2019-09-06 | 中国药科大学 | 五环三萜皂苷的医药用途及其药物组合物 |
-
2022
- 2022-04-20 CN CN202210416547.4A patent/CN114796293B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200981A (zh) * | 2019-06-06 | 2019-09-06 | 中国药科大学 | 五环三萜皂苷的医药用途及其药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114796293B (zh) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106924378B (zh) | 一种防治和/或治疗慢性唇炎的中草药唇膏 | |
| DE69730214T2 (de) | Zusammensetzung und verfahren zur behandlung von herpes simplex | |
| JP2008506718A (ja) | カラパ・ギアネンシス（Ｃａｒａｐａｇｕｉａｎｅｎｓｉｓ）由来の薬学的組成物 | |
| JP5406015B2 (ja) | 手・足白癬治療の製剤およびその製造方法 | |
| CN102335231B (zh) | 一种用于治疗黄褐斑的中药润肤霜及其制备方法和应用 | |
| CN116603012A (zh) | 一种中药凝胶及其制备方法和应用 | |
| JPH10120579A (ja) | 津液改善用皮膚外用剤 | |
| CN114796293B (zh) | 一种常春藤皂苷c的应用 | |
| CN111000913A (zh) | 一种治疗银屑病的中药组合物 | |
| CN112521389B (zh) | 用于促进伤口愈合的药物及方法 | |
| CN108785384A (zh) | 一种用于治疗痤疮的含锌中药组合物及其制剂 | |
| CN114712376A (zh) | 白头翁皂苷b4在制备外用治疗银屑病药物中的应用 | |
| JPH10120558A (ja) | 津液改善用皮膚外用剤 | |
| CN114948859A (zh) | 一种治疗泛发性皮炎的中药组合物皮肤用凝胶剂及其制备方法和应用 | |
| CN113181240A (zh) | 构树根皮在制备治疗特应性皮炎的药物上的应用 | |
| CN113230374A (zh) | 一种用于治疗宫寒的外用组方及制备方法与应用 | |
| CN113144115A (zh) | 一种治疗寻常疣的中药组合物及其应用 | |
| CN105362382A (zh) | 一种治疗复发性口腔溃疡中药组合物及其应用 | |
| CN107638497B (zh) | 一种治疗毒蛇咬伤的中药组合物及其制备方法和用途 | |
| JPS625126B2 (zh) | ||
| JPH10120556A (ja) | 津液改善用皮膚外用剤 | |
| JPH10120561A (ja) | 津液改善用皮膚外用剤 | |
| CN115192639B (zh) | 一种治疗湿疹的药物及其制备方法 | |
| CN108853246B (zh) | 一种消炎镇痛中药组合物及其制备方法和应用 | |
| CN111358927B (zh) | 蒲姜药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |